|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: ERI3 |
Gene summary for ERI3 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | ERI3 | Gene ID | 79033 |
| Gene name | ERI1 exoribonuclease family member 3 | |
| Gene Alias | PINT1 | |
| Cytomap | 1p34.1 | |
| Gene Type | protein-coding | GO ID | GO:0000459 | UniProtAcc | B4DN03 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 79033 | ERI3 | LZE7T | Human | Esophagus | ESCC | 5.66e-07 | 6.18e-01 | 0.0667 |
| 79033 | ERI3 | LZE8T | Human | Esophagus | ESCC | 8.15e-05 | 2.23e-01 | 0.067 |
| 79033 | ERI3 | LZE20T | Human | Esophagus | ESCC | 4.16e-08 | 2.18e-01 | 0.0662 |
| 79033 | ERI3 | LZE22T | Human | Esophagus | ESCC | 2.67e-03 | 5.58e-01 | 0.068 |
| 79033 | ERI3 | LZE24T | Human | Esophagus | ESCC | 4.24e-28 | 8.17e-01 | 0.0596 |
| 79033 | ERI3 | LZE21T | Human | Esophagus | ESCC | 4.02e-02 | 4.73e-01 | 0.0655 |
| 79033 | ERI3 | LZE6T | Human | Esophagus | ESCC | 8.35e-05 | 3.44e-01 | 0.0845 |
| 79033 | ERI3 | P1T-E | Human | Esophagus | ESCC | 9.37e-04 | 4.47e-01 | 0.0875 |
| 79033 | ERI3 | P2T-E | Human | Esophagus | ESCC | 1.24e-58 | 1.21e+00 | 0.1177 |
| 79033 | ERI3 | P4T-E | Human | Esophagus | ESCC | 4.56e-23 | 6.92e-01 | 0.1323 |
| 79033 | ERI3 | P5T-E | Human | Esophagus | ESCC | 9.75e-26 | 6.29e-01 | 0.1327 |
| 79033 | ERI3 | P8T-E | Human | Esophagus | ESCC | 7.85e-28 | 6.40e-01 | 0.0889 |
| 79033 | ERI3 | P9T-E | Human | Esophagus | ESCC | 1.34e-21 | 5.38e-01 | 0.1131 |
| 79033 | ERI3 | P10T-E | Human | Esophagus | ESCC | 2.13e-58 | 1.10e+00 | 0.116 |
| 79033 | ERI3 | P11T-E | Human | Esophagus | ESCC | 1.77e-24 | 8.54e-01 | 0.1426 |
| 79033 | ERI3 | P12T-E | Human | Esophagus | ESCC | 8.70e-34 | 6.48e-01 | 0.1122 |
| 79033 | ERI3 | P15T-E | Human | Esophagus | ESCC | 2.82e-23 | 6.70e-01 | 0.1149 |
| 79033 | ERI3 | P16T-E | Human | Esophagus | ESCC | 2.04e-44 | 7.59e-01 | 0.1153 |
| 79033 | ERI3 | P17T-E | Human | Esophagus | ESCC | 4.82e-16 | 8.30e-01 | 0.1278 |
| 79033 | ERI3 | P19T-E | Human | Esophagus | ESCC | 5.39e-16 | 1.82e+00 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Skin |  | AK: Actinic keratosis |
| cSCC: Cutaneous squamous cell carcinoma | ||
| SCCIS:squamous cell carcinoma in situ | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:001607232 | Thyroid | ATC | rRNA metabolic process | 161/6293 | 236/18723 | 1.02e-27 | 5.89e-25 | 161 |
| GO:003447021 | Thyroid | ATC | ncRNA processing | 216/6293 | 395/18723 | 3.14e-18 | 3.98e-16 | 216 |
| GO:003466021 | Thyroid | ATC | ncRNA metabolic process | 240/6293 | 485/18723 | 2.03e-13 | 9.91e-12 | 240 |
| GO:003112312 | Thyroid | ATC | RNA 3'-end processing | 65/6293 | 116/18723 | 5.58e-07 | 7.93e-06 | 65 |
| GO:000046911 | Thyroid | ATC | cleavage involved in rRNA processing | 21/6293 | 27/18723 | 3.28e-06 | 3.69e-05 | 21 |
| GO:009050112 | Thyroid | ATC | RNA phosphodiester bond hydrolysis | 76/6293 | 152/18723 | 2.07e-05 | 1.86e-04 | 76 |
| GO:000046012 | Thyroid | ATC | maturation of 5.8S rRNA | 24/6293 | 35/18723 | 2.49e-05 | 2.16e-04 | 24 |
| GO:009050312 | Thyroid | ATC | RNA phosphodiester bond hydrolysis, exonucleolytic | 27/6293 | 42/18723 | 4.62e-05 | 3.70e-04 | 27 |
| GO:000046611 | Thyroid | ATC | maturation of 5.8S rRNA from tricistronic rRNA transcript (SSU-rRNA, 5.8S rRNA, LSU-rRNA) | 15/6293 | 24/18723 | 3.52e-03 | 1.56e-02 | 15 |
| GO:003112511 | Thyroid | ATC | rRNA 3'-end processing | 8/6293 | 10/18723 | 3.60e-03 | 1.58e-02 | 8 |
| GO:009030511 | Thyroid | ATC | nucleic acid phosphodiester bond hydrolysis | 107/6293 | 261/18723 | 7.21e-03 | 2.84e-02 | 107 |
| Page: 1 2 3 4 5 6 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| ERI3 | SNV | Missense_Mutation | rs776082167 | c.563N>C | p.Val188Ala | p.V188A | O43414 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-A2-A0CS-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Hormone Therapy | anastrozole | SD |
| ERI3 | SNV | Missense_Mutation | c.775C>A | p.Gln259Lys | p.Q259K | O43414 | protein_coding | tolerated(0.45) | benign(0.005) | TCGA-A2-A25A-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unspecific | Cytoxan | SD | |
| ERI3 | SNV | Missense_Mutation | novel | c.266G>A | p.Arg89Gln | p.R89Q | O43414 | protein_coding | tolerated_low_confidence(0.13) | benign(0.116) | TCGA-2W-A8YY-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| ERI3 | SNV | Missense_Mutation | rs201922019 | c.167N>T | p.Ser56Leu | p.S56L | O43414 | protein_coding | tolerated_low_confidence(0.15) | benign(0) | TCGA-JX-A3Q0-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| ERI3 | SNV | Missense_Mutation | rs779614935 | c.890G>A | p.Gly297Asp | p.G297D | O43414 | protein_coding | tolerated(0.58) | benign(0.094) | TCGA-A6-5661-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| ERI3 | SNV | Missense_Mutation | c.350N>T | p.Ser117Phe | p.S117F | O43414 | protein_coding | deleterious(0) | possibly_damaging(0.601) | TCGA-AA-3675-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ERI3 | SNV | Missense_Mutation | c.373G>A | p.Ala125Thr | p.A125T | O43414 | protein_coding | tolerated(0.12) | benign(0) | TCGA-AD-5900-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| ERI3 | SNV | Missense_Mutation | c.427N>C | p.Tyr143His | p.Y143H | O43414 | protein_coding | deleterious(0) | benign(0.309) | TCGA-AY-6197-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ERI3 | SNV | Missense_Mutation | c.950N>T | p.Ala317Val | p.A317V | O43414 | protein_coding | tolerated(0.09) | possibly_damaging(0.851) | TCGA-D5-6530-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
| ERI3 | SNV | Missense_Mutation | novel | c.388G>A | p.Ala130Thr | p.A130T | O43414 | protein_coding | tolerated(0.06) | benign(0.03) | TCGA-AG-A002-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |